摘要
随着年龄的增长,慢性阻塞性肺疾病(COPD)合并各种常见慢性心血管疾病的概率逐年增加,而这些合并症的存在也是COPD患者住院和死亡的主要原因之一。对于COPD,临床上用β2受体激动剂来扩张支气管平滑肌,改善肺通气,而对于伴随的慢性心血管疾病,临床上多采用β1受体拮抗剂治疗。β1受体和β2受体同时存在于心血管和肺组织,所占比例不尽相同,通过查阅近10年来国内外文献,发现当用β1受体拮抗剂治疗COPD所合并的心血管疾病时,其对于主症COPD是安全的,同时还可减少COPD急性加重、改善呼吸功能及降低病死率。
Chronic obstructive pulmonary disease (COPD) associated with a variety of common chronic cardiovascular diseases increases with age, and the presence of these complications is one of the major causes of hospitalization and death in COPD patients.For COPD, beta-2 receptor agonists are clinically used to dilate bronchial smooth muscle and improve pulmonary ventilation, while beta-1 receptor antagonists are clinically used to treat concomitant chronic cardiovascular diseases.Both beta-1 receptor and beta-2 receptor are present in cardiovascular and lung tissues, and the proportion is different.The authors have reviewed the literatures of domestic and foreign for nearly 10 years and found that when using beta-1 receptor antagonist to treat vascular disease which is combined with COPD, it is safe for the main COPD, and it can also reduce the acute exacerbation of COPD, improve respiratory function and reduce fatality rate.
作者
牛茜
陶晓南
Niu Qian;Tao Xiaonan(Department of Respiratory and Critical Care Medicine,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430000,China)
出处
《国际呼吸杂志》
2019年第11期861-864,共4页
International Journal of Respiration
关键词
肺疾病
慢性阻塞性
心血管疾病
肾上腺素β1受体拮抗剂
Pulmonary disease, chronic obstructive
Cardiovascular disease
Adrenergic beta-1 receptor antagonists
